Orange Ribbon

A dedicated group of UPCI investigators are engaged in collaborative basic, clinical, and translational research aimed at understanding the molecular pathogenesis of hematological malignancies and progression, and their response to treatment. UPCI's overall scientific goals in blood disease research are to:

  • increase our understanding of the molecular and cellular biology of normal and leukemic stem cell formation, and the impact of the bone marrow microenvironment on normal and malignant cell formation;
  • uncover the molecular basis of blood cancers and their resistance to therapy;
  • identify and validate clinically relevant biomarkers of disease; and
  • use this information to develop novel, preventive, diagnostic, and therapeutic strategies for treating blood cancers.

The program is divided into four major research areas:

  • myeloid malignancies
  • lymphoid malignancies
  • multiple myeloma
  • stem cell transplantation
Investigators are engaged in molecular and preclinical studies that form the intellectual and experimental basis for novel preventive, diagnostic and therapeutic approaches, and are leading innovative clinical trials, with the overall aim of improving outcomes of patients with hematologic malignancies.

The extensive scientific resources and expertise at UPCI have enabled the program to build research strengths in areas relevant to its overall goals, including signaling pathways involved in normal and cancerous formation of blood cells, stem cell division and differentiation, the role of the bone marrow microenvironment in blood cancers, immunobiology of stem cell transplantation, and development of targeted agents for the treatment of blood cancers.

For Patients

For more information on hematologic malignancies and treatment options, visit the UPMC CancerCenter Hematological Malignancies site, or click here to find a clinical trial.